Skip to content

A Double-Blind Randomized Study Comparing Dexketoprofen and Ketorolac in Local Infiltration Analgesia for Reducing Blood Loss and Improving Pain Control After Total Knee Arthroplasty.

A Double-Blind Randomized Study Comparing Dexketoprofen and Ketorolac in Local Infiltration Analgesia for Reducing Blood Loss and Improving Pain Control After Total Knee Arthroplasty.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260201005
Enrollment
62
Registered
2026-02-01
Start date
2026-01-14
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Postoperative Pain (Ketorolac and Dexketoprofen) 2.Knee Osteoarthritis 3.Total Knee Arthroplasty Ketorolac, Dexketoprofen, Local infiltration analgesia, Total knee arthroplasty, post operative pain

Interventions

- A 40 ml Local Infiltration Analgesia (LIA) cocktail consisting of 30 mg Ketorolac mixed with 20 ml of 0.5% Bupivacaine, 0.3 ml of Adrenaline (1:1000), and Normal Saline Solution (NSS) to reach a tot
Active Comparator Drug,Experimental Drug
Ketorolac group ,Dexketoprofen group

Sponsors

Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary varus osteoarthritis of the knee. 2. Patients undergoing unilateral total knee arthroplasty (TKA). 3.Patients with a range of motion (ROM) of the knee: extension between 0 to 5 degrees and flexion of at least 120 degrees. 4.Patients with no prior history of knee surgery.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of hypersensitivity or allergy to the study drugs. 2.Patients with a history of prior knee surgery. 3.Patients with a history of prior knee joint infection. 4.Patients with renal impairment (serum creatinine > 1.5 mg/dL). 5.Patients with a history of venous thromboembolism (VTE). 6.Patients with a history of gastrointestinal (GI) bleeding.

Design outcomes

Primary

MeasureTime frame
postoperative pain postoperative at 6,12,24,48,72 hours VAS at rest and on motion,Blood loss postoperative at 24 hours Predicted Blood Loss; PBL

Secondary

MeasureTime frame
Range of motion postoperative at 6,12,24,48,72 hours goniometer ,Complication postoperative at day 0, 1, 2, 3 Medical record form clinical, lab investigation eg. creatinine,Morphine consumption postoperative at day 0, 1, 2, 3 medical record

Countries

Thailand

Contacts

Public ContactSirasit Innarkgolol

Orthopedics department, Faculty of medicine, Chulalongkorn University

sirasit.inn@chulahospital.org022564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026